| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
BASEL, Switzerland—Halozyme Therapeutics announced that it has entered into an agreement with Roche to apply its Enhanze Technology to a panel of biologicals from Roche. The deal will see Roche pay the Swiss company $20 million upfront and will retain the rights to develop Halozyme's drug delivery technology with ten other agents over the next ten years. The deal, including milestone and royalty payments, is valued around $600 million.
 
"We believe that our technology can enhance the clinical benefits that biologics have already been shown to provide," said Dr. Jonathan Lim, Halozyme president and CEO. "In every respect, both technically and commercially, this represents a landmark agreement for Enhanze Technology and for Halozyme."
 
The deal will also see an $11-million equity investment by Roche Venture Fund, representing about 5 percent of Halozyme's outstanding common stock.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue